Type I interferons mediate pancreatic toxicities of PERK inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Significance: Inactivating pancreatic endoplasmic reticulum kinase (PERK) mutations cause pancreatic degeneration and diabetes in patients with Wolcott-Rallison syndrome. Pancreatic injury is also observed in mice upon PERK genetic ablation or treatment with PERK inhibitors. This toxicity (the mechanisms of which are poorly understood) impedes the clinical development of PERK inhibitors, which show promise against cancers and neurodegenerative diseases. Here we demonstrate that activation of type 1 interferon signaling occurs upon PERK ablation and is responsible for pancreatic injury and the loss of exocrine and endocrine tissues and functions. Neutralization of interferon signaling protects the pancreas from deleterious effects of PERK inhibitors. Temporally targeting the interferon pathway may help with the treatment of patients with Wolcott-Rallison syndrome and the use of PERK inhibitors against other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moreno, J. A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J. M., Ortori, C. A., Willis, A. E., Fischer, P. M., Barrett, D. A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006767 · Cited by 589 · cited 2×
“Furthermore, some of these inhibitors can protect against the prion-mediated neurogenerative disorders (25).”
BackgroundTargeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70454 · Cited by 457
Self-citationCharacterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3109 · Cited by 443 · cited 1×
“Consistent with previously published reports (22), extended treatment with PERK inhibitor markedly decreased pancreas weight in wild-type mice (Fig.”
ResultER Stress, Hypoxia Tolerance and Tumor Progression
Koumenis, C. (2006) · Current Molecular Medicine · doi:10.2174/156652406775574604 · Cited by 231
Self-citationPiehler, J., Thomas, C., Garcia, K. C., & Schreiber, G. (2012) · Immunological Reviews · doi:10.1111/imr.12001 · Cited by 230
Cited by
The integrated stress response: From mechanism to disease
Costa-Mattioli, M., & Walter, P. (2020) · Science · doi:10.1126/science.aat5314 · Cited by 1,617
Endoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
Pharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Translation deregulation in human disease
Tahmasebi, S., Khoutorsky, A., Mathews, M. B., & Sonenberg, N. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0034-x · Cited by 255
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
Metadata
- Authors
- Yu, Q., Zhao, B., Gui, J., Katlinski, K. V., Brice, A., Gao, Y., Li, C., Kushner, J. A., Koumenis, C., Diehl, J. A., & Fuchs, S. Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-12
- Volume
- 112
- Issue
- 50
- Pages
- 15420-15425
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2285866654
- Cited by
- 71
- References
- 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type I interferons mediate pancreatic toxicities of PERK inhibition. https://app.cochat.ai/papers/10.1073/pnas.1516362112
- The paper
- Yu, Q., Zhao, B., Gui, J., Katlinski, K. V., Brice, A., Gao, Y., Li, C., Kushner, J. A., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2015). Type I interferons mediate pancreatic toxicities of PERK inhibition. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1516362112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.